Why the study?
Does rivaroxaban added to dual antiplatelet therapy reduce the composite endpoint of cardiovascular death, myocardial infarction and stroke in patients with stabilised acute coronary syndrome?
Does rivaroxaban added to dual antiplatelet therapy reduce the composite endpoint of cardiovascular death, myocardial infarction and stroke in patients with stabilised acute coronary syndrome?
A dual-pathway approach combining rivaroxaban and dual antiplatelet therapy reduces recurrent ischemic events and mortality in stabilized ACS patients, despite an increased bleeding risk.
No takes yet. Share an insight, caveat, or question.
Supports dual-pathway inhibition in stabilized ACS; leaves open confirmation in contemporary randomized trials.
Jeffrey I. Weitz (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: